MiR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells

Digestive Diseases and Sciences

Volumn 59, Issue 2, 2014, Pages 336-345

  Hu, Jianghong ^a   Fang, Yue ^b   Cao, Yuan ^b   Qin, Rong ^b   Chen, Qiaoyun ^b  

^a Danyang People's Hospital   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

BCL2 protein; Cyclin D1 protein; Gastric cancer; miR 449a

Indexed keywords

CISPLATIN; CYCLIN D1; MICRORNA; MICRORNA 449A; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MTT ASSAY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME FACTORS; TRANSFECTION;

EID: 84896724947     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2923-3     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27-39.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
4. Liu K, Qian T, Tang L, et al. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol. 2012;10:225.
5. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-355.
6. de Moor CH, Meijer H, Lissenden S. Mechanisms of translational control by the 3′ UTR in development and differentiation. Semin Cell Dev Biol. 2005;16:49-58.
7. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7:2152-2159.
8. Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113:249-255.
9. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8:266.
10. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008;68:10307-10314.
11. Noonan EJ, Place RF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009;28:1714-1724.
12. Lize M, Pilarski S, Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2010;17:452-458.
13. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer. 2011;10:29.
14. Capuano M, Iaffaldano L, Tinto N, et al. MicroRNA-449a overexpression, reduced NOTCH1 signals and scarce goblet cells characterize the small intestine of celiac patients. PLoS One. 2011;6:e29094.
15. Biliran H Jr, Wang Y, Banerjee S, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:6075-6086.
16. Dai ZJ, Gao J, Ji ZZ, et al. Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3. J Ethnopharmacol. 2009;123:91-96.
17. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
18. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clinical Oncol Off J Am Soc ClinOncol. 2009;27:5848-5856.
19. Chen H, Lin YW, Mao YQ, et al. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett. 2012;320:40-47.
20. Yang X, Feng M, Jiang X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388-2393.
21. Fu M, Wang C, Li Z, et al. Minireview: cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439-5447.
22. Schultz J, Lorenz P, Gross G, et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18:549-557.
23. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129-1132.
24. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123:372-379.
25. Zhu W, Shan X, Wang T, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127:2520-2529.